Here are 1-3 brief analogies for Tempus AI (TEM):

• Palantir for precision medicine. (Highlights its role in integrating vast, disparate data and applying AI for complex problem-solving in healthcare.)
• An AI-powered Google for medical insights. (Emphasizes its use of AI to organize and provide actionable intelligence from massive medical datasets.)
• A supercharged 23andMe for doctors and researchers. (Points to its use of genomic data combined with comprehensive clinical data and AI, but for professional medical decision-making rather than consumer-facing insights.)

• Genomic Sequencing & Profiling: Tempus provides comprehensive genomic sequencing and molecular profiling services for cancer and other diseases to identify actionable biomarkers.
• AI-Powered Precision Medicine Platform: This platform integrates clinical and molecular data, leveraging AI to offer physicians personalized insights and treatment recommendations for patients.
• Real-World Data & Analytics: Tempus offers de-identified real-world data and advanced analytics solutions to biopharmaceutical companies and researchers for drug discovery and development.
• Clinical Trial Matching: Utilizing its extensive data and AI, Tempus identifies and matches eligible patients with relevant clinical trials to accelerate research.

Tempus AI (symbol: TEM) primarily sells its services and technology to other companies (a Business-to-Business, or B2B, model). While Tempus AI does not publicly disclose the specific names of individual companies that represent its "major customers" in its SEC filings, its customer base can be categorized into the following groups:

• Healthcare Providers: This category includes hospitals, large health systems, and academic medical centers. These organizations utilize Tempus's platforms for genomic sequencing, molecular and clinical data analysis, and AI-powered insights to guide patient care and treatment decisions.
• Life Sciences Companies: This encompasses pharmaceutical companies and biotechnology companies. Tempus provides them with access to its vast real-world data (RWD) sets, advanced analytical services, and AI models. This supports drug discovery and development, clinical trial optimization, identification of biomarkers, and market access strategies. While specific names of individual customer companies are not disclosed, this category would include numerous public and private entities within the biopharmaceutical sector.
• Research Institutions: Academic institutions and other research organizations leverage Tempus's data and analytical capabilities for scientific research and advancements in precision medicine.

• Google Cloud (GOOGL)
• Illumina (ILMN)

Eric Lefkofsky Founder & CEO

Eric Lefkofsky founded Tempus AI in 2015 and has served as its Chief Executive Officer and a board member since its inception. Prior to Tempus AI, Mr. Lefkofsky co-founded Groupon, Inc. in 2008, where he held roles including Executive Chairman, Chief Executive Officer, and Chairman of the board of directors. He also co-founded Lightbank LLC, a private venture capital firm. His entrepreneurial ventures include co-founding Echo Global Logistics, InnerWorkings, and Mediaocean. Early in his career, he co-founded Starbelly, which was sold to Halo Industries. Groupon later raised significant private funding, with a portion paid out to employees and investors, including Mr. Lefkofsky.

James Rogers Chief Financial Officer

James Rogers joined Tempus AI in 2017 as the company's first finance hire when it was pre-revenue, building out the finance function. He became Chief Financial Officer in 2021 and was instrumental in steering the company public. Earlier in his career, Mr. Rogers began in audit at Ernst & Young and later advanced to head of FP&A for North America at Groupon.

Ryan Fukushima Chief Operating Officer

Ryan Fukushima joined Tempus AI as the company's first employee in 2015, shortly after Eric Lefkofsky founded the company. He currently serves as the Chief Operating Officer.

Shane Colley Chief Technology Officer

Shane Colley is the Chief Technology Officer at Tempus AI.

Stacey Kraft Chief People Officer

Stacey Kraft holds the position of Chief People Officer at Tempus AI.

Major technology companies (e.g., Google, Microsoft) with vast resources in AI and cloud computing are increasingly investing in and expanding into healthcare data analytics and AI-driven precision medicine platforms. These companies possess the capability to build comprehensive multimodal data aggregation and analysis platforms that could directly compete with or even surpass Tempus AI's offerings, leveraging their scalable infrastructure, advanced AI research, and existing healthcare partnerships.

The estimated addressable market for Tempus AI's main products and services is approximately $200 billion. While the specific geographic region for this valuation is not explicitly stated as "U.S." or "global" in the provided information, Tempus AI's significant operational footprint and partnerships are largely concentrated within the United States.

Tempus AI (TEM) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends:

1. Growth in Genomic Testing Volumes and Average Selling Prices (ASPs): Tempus AI anticipates continued strong performance in its genomic testing segment, particularly in oncology and hereditary testing. In Q3 2025, oncology testing revenue increased by 31.7% year-over-year, driven by a 27% rise in volume, and hereditary testing saw a 32.8% increase in revenue with 37% volume growth. The company expects to sustain a 25% growth rate in oncology over the next three years. Analysts project that average selling prices will also increase as the product mix shifts towards higher-priced tests, such as the xT CDx and the xF liquid biopsy assay.
2. Expansion of Data and Services (Insights) Business: The company's data licensing or "insights" business demonstrated robust growth, with a 38% increase in the third quarter of 2025 and an additional $150 million in total contract value. Tempus AI is actively securing additional contracts with pharmaceutical companies for its data and services, with the total remaining contract value for data services exceeding $1 billion as of April 30, 2025. These strategic partnerships, including a notable $200 million, three-year agreement with AstraZeneca and Pathos, are central to driving growth and product development.
3. Launch and Reimbursement of New Products and Technologies: Tempus AI expects to benefit from the planned regulatory filing of its liquid biopsy xF later this year, which is projected to provide additional tailwind in both unit volume and revenue for that business. The expansion of commercial payor coverage for tests like xF and xT CDx is also anticipated, with Advanced Diagnostic Laboratory Test (ADLT) status potentially offering upside in reimbursement levels. The company has also received FDA clearance for several AI-powered medical devices and introduced Tempus xM for treatment and response monitoring.
4. Strategic Acquisitions and AI-Powered Solutions: The acquisition of Paige, an AI company specializing in digital pathology, is a strategic move to expand Tempus AI's operations and is expected to contribute to future revenue growth through expanded offerings and market reach. Tempus AI is focused on embedding AI, including generative AI, across all aspects of diagnostics to enable personalized, data-driven decisions and improve patient care. This includes the rollout of platforms like Tempus Next care pathway intelligence, designed to provide AI-driven decision support in oncology.
5. Increased Market Penetration in Precision Medicine and Oncology: Tempus AI is strategically positioned at the intersection of precision medicine, oncology, and artificial intelligence, which are rapidly expanding markets. The company aims to grow its customer base by increasing penetration among pharmaceutical companies, healthcare providers, and research institutions, leveraging its extensive library of clinical and molecular oncology data.

Share Repurchases

• Tempus AI engaged in share buyback activities in early 2025, including acquiring 311,988 ordinary shares at 1.70 pounds each and 200,000 shares at 1.67 pounds per share in January 2025.
• Over recent weeks in early 2025, Tempus AI continued its share buyback strategy by acquiring an additional 170,447 shares at 1.65 pounds each.
• A strategic share buyback action has reduced outstanding shares, aiming to solidify market position and hint at financial optimism.

Share Issuance

• Tempus AI completed its Initial Public Offering (IPO) on June 14, 2024, issuing 11.1 million shares of Class A common stock at $37.00 per share, which raised approximately $410.7 million in gross proceeds.
• The company issued $750 million of 0.75% convertible senior notes in the second quarter of 2025.
• Tempus had previously confidentially filed for an S-1 registration on September 1, 2021, and officially filed its S-1 registration statement in May 2024.

Inbound Investments

• Prior to its IPO, Tempus AI accumulated over $1 billion in private funding across multiple rounds between 2015 and 2023.
• In 2020, Google's venture arm contributed $200 million as part of a funding round that valued Tempus at $8.1 billion, intended to support expansion into infectious disease, depression, and cardiology.
• In February 2025, Ares Management provided a $300 million debt financing package, and a strategic partnership with AstraZeneca and Pathos in Q1 2025 resulted in Tempus receiving $200 million in data licensing and model development fees over three years.

Outbound Investments

• In February 2022, Tempus AI acquired Highline Sciences (also referred to as Highline Consulting), a clinical contract research organization focused on oncology.
• The company completed the acquisition of Ambry Genetics, a genetic testing company, in February 2025, following its announcement in November 2024 for $600 million (paid with $375 million in cash and $225 million in stock).
• Tempus AI acquired Deep 6 AI, an AI-driven clinical trial recruitment platform, in March 2025, and Paige, an AI company specializing in digital pathology, in August 2025 for $81.25 million, predominantly paid in common stock.

Capital Expenditures

• Tempus AI's annual capital expenditures were $18.377 million in 2022, $34.608 million in 2023, and $22.121 million in 2024.
• For the first and second quarters of 2025, capital expenditures were $3.372 million and $9.511 million, respectively.
• The capital expenditures are primarily focused on ongoing investment in infrastructure and product development to support its AI-driven solutions and genomics business.